Abivax SA American Depositary Shares (ABVX) stock price

Abivax SA American Depositary Shares (ABVX) is a Healthcare · Biotechnology company listed on NASDAQ. Price $105.04 (-1.82%), Market cap $9.83B, 52-week low–high $5.67 ~ $145.31.

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Key metrics

Financial statements, price targets, institutional (13F) holdings and related news for Abivax SA American Depositary Shares are updated in real time on BlackAll Trade.

Abivax SA American Depositary Shares financial summary

Analyst outlook

Key ratios · profitability · growth

Frequently asked questions

What is the current Abivax SA American Depositary Shares (ABVX) stock price?

Abivax SA American Depositary Shares trades at $105.04 (-1.82%). Real-time quotes and charts are available on BlackAll Trade.

What is the Abivax SA American Depositary Shares (ABVX) market cap?

Abivax SA American Depositary Shares has a market cap of about $9.83B.

What does Abivax SA American Depositary Shares (ABVX) do?

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic in